Long-term outcome after implantation of a suprachoroidal cyclosporine drug delivery device in horses with recurrent uveitis

Brian C. Gilger, David A. Wilkie, Allison B. Clode, Richard J. McMullen, Mary Utter, Andras M. Komaromy, Dennis E. Brooks, Jacklin H. Salmon

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Objective: To determine the long-term efficacy, complications, and duration of effect of a cyclosporine (CsA) suprachoroidal implant (CSI) in horses with equine recurrent uveitis (ERU). Methods: Horses with ERU were treated with a 6-mm diameter, 25 mg, reservoir matrix CsA implant in the deep sclera adjacent to the suprachoroidal space. Horses with follow-up >1 year were examined for frequency of uveitis episodes, complications, and vision at last recheck. Results: Data from 151 eyes of 133 horses from the USA and Europe that had CsA devices implanted for ERU were reviewed. Follow-up time ranged from 13 to 85 months after surgery, with a mean and median follow-up time of 28.9 and 26.3 months, respectively. Overall, at last follow-up 78.8% of eyes were considered visual and the overall mean frequency of uveitis episodes after CSI was 0.09 ± SD 0.08 episodes per month. The most common complications leading to vision loss at last follow-up were persistent uveitis episodes (54%), glaucoma (22%), mature cataracts (16%), and retinal detachment (6%). Persistent uveitis episodes tended to be the highest cause of vision loss in horses with <24 months and >48 months of follow-up. Conclusions: This study demonstrated the long-term maintenance of vision of horses with ERU implanted with a CSI. The increased vision loss related to uveitis episode of inflammation in eyes after the likely depletion of CsA from the CSI suggests that a repeat CSI may be required at or before 48 months after surgery.

Original languageEnglish (US)
Pages (from-to)294-300
Number of pages7
JournalVeterinary Ophthalmology
Volume13
Issue number5
DOIs
StatePublished - Sep 1 2010
Externally publishedYes

Fingerprint

cyclosporine
Uveitis
Cyclosporine
Horses
horses
drugs
Equipment and Supplies
Pharmaceutical Preparations
eyes
surgery
glaucoma
Sclera
cataract
Retinal Detachment
Glaucoma
Cataract
inflammation
Inflammation

Keywords

  • Cyclosporine
  • Equine
  • Implant
  • Recurrent uveitis

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Long-term outcome after implantation of a suprachoroidal cyclosporine drug delivery device in horses with recurrent uveitis. / Gilger, Brian C.; Wilkie, David A.; Clode, Allison B.; McMullen, Richard J.; Utter, Mary; Komaromy, Andras M.; Brooks, Dennis E.; Salmon, Jacklin H.

In: Veterinary Ophthalmology, Vol. 13, No. 5, 01.09.2010, p. 294-300.

Research output: Contribution to journalArticle

Gilger, Brian C. ; Wilkie, David A. ; Clode, Allison B. ; McMullen, Richard J. ; Utter, Mary ; Komaromy, Andras M. ; Brooks, Dennis E. ; Salmon, Jacklin H. / Long-term outcome after implantation of a suprachoroidal cyclosporine drug delivery device in horses with recurrent uveitis. In: Veterinary Ophthalmology. 2010 ; Vol. 13, No. 5. pp. 294-300.
@article{07e247c7a1124095a3711e95f8fdaab8,
title = "Long-term outcome after implantation of a suprachoroidal cyclosporine drug delivery device in horses with recurrent uveitis",
abstract = "Objective: To determine the long-term efficacy, complications, and duration of effect of a cyclosporine (CsA) suprachoroidal implant (CSI) in horses with equine recurrent uveitis (ERU). Methods: Horses with ERU were treated with a 6-mm diameter, 25 mg, reservoir matrix CsA implant in the deep sclera adjacent to the suprachoroidal space. Horses with follow-up >1 year were examined for frequency of uveitis episodes, complications, and vision at last recheck. Results: Data from 151 eyes of 133 horses from the USA and Europe that had CsA devices implanted for ERU were reviewed. Follow-up time ranged from 13 to 85 months after surgery, with a mean and median follow-up time of 28.9 and 26.3 months, respectively. Overall, at last follow-up 78.8{\%} of eyes were considered visual and the overall mean frequency of uveitis episodes after CSI was 0.09 ± SD 0.08 episodes per month. The most common complications leading to vision loss at last follow-up were persistent uveitis episodes (54{\%}), glaucoma (22{\%}), mature cataracts (16{\%}), and retinal detachment (6{\%}). Persistent uveitis episodes tended to be the highest cause of vision loss in horses with <24 months and >48 months of follow-up. Conclusions: This study demonstrated the long-term maintenance of vision of horses with ERU implanted with a CSI. The increased vision loss related to uveitis episode of inflammation in eyes after the likely depletion of CsA from the CSI suggests that a repeat CSI may be required at or before 48 months after surgery.",
keywords = "Cyclosporine, Equine, Implant, Recurrent uveitis",
author = "Gilger, {Brian C.} and Wilkie, {David A.} and Clode, {Allison B.} and McMullen, {Richard J.} and Mary Utter and Komaromy, {Andras M.} and Brooks, {Dennis E.} and Salmon, {Jacklin H.}",
year = "2010",
month = "9",
day = "1",
doi = "10.1111/j.1463-5224.2010.00807.x",
language = "English (US)",
volume = "13",
pages = "294--300",
journal = "Veterinary Ophthalmology",
issn = "1463-5216",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Long-term outcome after implantation of a suprachoroidal cyclosporine drug delivery device in horses with recurrent uveitis

AU - Gilger, Brian C.

AU - Wilkie, David A.

AU - Clode, Allison B.

AU - McMullen, Richard J.

AU - Utter, Mary

AU - Komaromy, Andras M.

AU - Brooks, Dennis E.

AU - Salmon, Jacklin H.

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Objective: To determine the long-term efficacy, complications, and duration of effect of a cyclosporine (CsA) suprachoroidal implant (CSI) in horses with equine recurrent uveitis (ERU). Methods: Horses with ERU were treated with a 6-mm diameter, 25 mg, reservoir matrix CsA implant in the deep sclera adjacent to the suprachoroidal space. Horses with follow-up >1 year were examined for frequency of uveitis episodes, complications, and vision at last recheck. Results: Data from 151 eyes of 133 horses from the USA and Europe that had CsA devices implanted for ERU were reviewed. Follow-up time ranged from 13 to 85 months after surgery, with a mean and median follow-up time of 28.9 and 26.3 months, respectively. Overall, at last follow-up 78.8% of eyes were considered visual and the overall mean frequency of uveitis episodes after CSI was 0.09 ± SD 0.08 episodes per month. The most common complications leading to vision loss at last follow-up were persistent uveitis episodes (54%), glaucoma (22%), mature cataracts (16%), and retinal detachment (6%). Persistent uveitis episodes tended to be the highest cause of vision loss in horses with <24 months and >48 months of follow-up. Conclusions: This study demonstrated the long-term maintenance of vision of horses with ERU implanted with a CSI. The increased vision loss related to uveitis episode of inflammation in eyes after the likely depletion of CsA from the CSI suggests that a repeat CSI may be required at or before 48 months after surgery.

AB - Objective: To determine the long-term efficacy, complications, and duration of effect of a cyclosporine (CsA) suprachoroidal implant (CSI) in horses with equine recurrent uveitis (ERU). Methods: Horses with ERU were treated with a 6-mm diameter, 25 mg, reservoir matrix CsA implant in the deep sclera adjacent to the suprachoroidal space. Horses with follow-up >1 year were examined for frequency of uveitis episodes, complications, and vision at last recheck. Results: Data from 151 eyes of 133 horses from the USA and Europe that had CsA devices implanted for ERU were reviewed. Follow-up time ranged from 13 to 85 months after surgery, with a mean and median follow-up time of 28.9 and 26.3 months, respectively. Overall, at last follow-up 78.8% of eyes were considered visual and the overall mean frequency of uveitis episodes after CSI was 0.09 ± SD 0.08 episodes per month. The most common complications leading to vision loss at last follow-up were persistent uveitis episodes (54%), glaucoma (22%), mature cataracts (16%), and retinal detachment (6%). Persistent uveitis episodes tended to be the highest cause of vision loss in horses with <24 months and >48 months of follow-up. Conclusions: This study demonstrated the long-term maintenance of vision of horses with ERU implanted with a CSI. The increased vision loss related to uveitis episode of inflammation in eyes after the likely depletion of CsA from the CSI suggests that a repeat CSI may be required at or before 48 months after surgery.

KW - Cyclosporine

KW - Equine

KW - Implant

KW - Recurrent uveitis

UR - http://www.scopus.com/inward/record.url?scp=77956295513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956295513&partnerID=8YFLogxK

U2 - 10.1111/j.1463-5224.2010.00807.x

DO - 10.1111/j.1463-5224.2010.00807.x

M3 - Article

VL - 13

SP - 294

EP - 300

JO - Veterinary Ophthalmology

JF - Veterinary Ophthalmology

SN - 1463-5216

IS - 5

ER -